Previous 10 | Next 10 |
Continued Enrollment in Monotherapy Dose Escalation Stage of Phase 1/2 MYCHELANGELO™ I Study; Preliminary First-in-Human Safety, Tolerability, Pharmacologic and Translational Data Anticipated in the Fourth Quarter of 2023 Presented New Preclinical Data at the American Society of Cl...
2023-08-01 16:29:26 ET Summary OMGA has an early stage program targeting various cancers using epigenetics. They are backed by a VC and have a decent cash runway. Though too early stage for my liking, OMGA is interesting. Omega Therapeutics ( OMGA ) develops epig...
2023-07-12 17:31:16 ET Gainers: Evolus ( NASDAQ: EOLS ) +5% . Omega Therapeutics ( OMGA ) +5% . Kodiak Sciences ( KOD ) +4% . Amazon ( AMZN ) +4% . Cara Therapeutics ( CARA ) +3% . Losers: ViaSat ( VSAT ) -7% ...
CAMBRIDGE, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the appointment of Chris Schade to its B...
REDWOOD CITY, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced th...
MYC-targeting Omega Epigenomic Controllers (OECs) Demonstrated Consistent Anti-Tumor Activity Across Multiple Tumor Types, Including Hepatocellular Carcinoma and Non-Small Cell Lung Cancer, in Preclinical Models MYC OECs Modulate Tumor Microenvironment, Enhanced Response to Checkpoint...
Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry PR Newswire The company's MIMiC™ platform drives unprecedented insights into molecular interactions to design new biomolecules precisely tuned for therapeutic benefi...
2023-05-10 15:28:29 ET Summary Among US-listed biotech stocks with promising prospects, investors should consider holding a position in Omega Therapeutics, Inc. as the company calls 2023 a pivotal year. Omega Therapeutics is a clinical-stage developer of controllers of the epigene...
2023-05-04 10:42:27 ET Omega Therapeutics press release ( NASDAQ: OMGA ): Q1 GAAP EPS of -$0.50 beats by $0.13 . Revenue of $0.52M (+92.6% Y/Y) beats by $0.21M . For further details see: Omega Therapeutics GAAP EPS of -$0.50 beats by $0.13, revenue of $0....
Continued to Advance Monotherapy Dose Escalation Stage of Ongoing Phase 1/2 MYCHELANGELO™ I Study; Preliminary Data Anticipated in 2023 Announced Clinical Supply Agreement with Roche to Evaluate OTX-2002 in Combination with Atezolizumab in MYCHELANGELO I Study Advanced Othe...
News, Short Squeeze, Breakout and More Instantly...
Omega Therapeutics Inc. Company Name:
OMGA Stock Symbol:
NASDAQ Market:
Omega Therapeutics Inc. Website:
CAMBRIDGE, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the election of Richard N. Kender to its...
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will participate in fires...
CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the appointment of Kaan Certel, Ph.D., as...